ZHUHAI, China, March 2, 2021 / PRNewswire / – Biotheus announced the successful conclusion of a fourth round of funding, co-led by General Atlantic, a leading global growth equity investor, and IDG Capital, a leading investment in the world. Other new investors include Kunlun Capital, CPE and Cowin Capital, with participation from former investors Highlight Capital, Shiyu Capital, New Alliance Capital, Huajin Investment, etc.
Founded in 2018, Biotheus is a company in clinical development whose mission is to treat cancer and autoimmune diseases through next-generation therapies. This is supported by the company’s product portfolio, which includes more than 10 novel monoclonal and multispecific antibodies. Biotheus currently has two bispecific antibodies in phase I clinical development for the treatment of cancer, and a third IND application was submitted at the end of 2020. With this new investment, Biotheus will further increase its investment in its research activities with the aim of to have five new ones. drugs in clinical development by the end of 2021, and drive several programs towards advanced clinical development.
Regarding this round of funding, Mr. Xiaolin Liu, President and CEO of Biotheus, said, “We are pleased that our efforts have been recognized and supported by leading investors like General Atlantic and IDG Capital. The continued support of our previous investors is also a testament to our company’s progress, execution and strength of…
News Highlights Finance
- Headline: Biotheus announces the closing of a new round of financing co-led by General Atlantic and IDG Capital
- Check all news and articles from the Finance news updates.